MYOT

Across TCGA pan-cancer cohorts, MYOT mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYOT data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MYOT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYOT expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC and HNSC are the cancer types where MYOT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.326	0.872	.024	2	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYOT–LSCC (DFS)

Open the LSCC breakdown →